Clinical Trials Directory

Trials / Unknown

UnknownNCT01680523

Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)

A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
409 (estimated)
Sponsor
Asan Medical Center · Academic / Other
Sex
Female
Age
20 Years – 75 Years
Healthy volunteers
Not accepted

Summary

To compare 5-year overall survival between patients who undergo radical hysterectomy followed by tailored adjuvant therapy and patients who receive primary chemoradiation therapy in FIGO stage IB2 and IIA2 cervical cancer

Conditions

Interventions

TypeNameDescription
PROCEDURERadical hysterectomyPiver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
RADIATIONTailored adjuvant therapyAfter radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
RADIATIONPrimary chemoradiation therapyPatient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.

Timeline

Start date
2012-09-01
Primary completion
2020-07-01
Completion
2020-07-01
First posted
2012-09-07
Last updated
2017-05-31

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01680523. Inclusion in this directory is not an endorsement.